Merck
CN

P2700000

泼尼松龙

European Pharmacopoeia (EP) Reference Standard

登录查看公司和协议定价

别名:
1,4-孕甾二烯-11β,17α,21-三醇-3,20-二酮, 1-去氢氢化可的松, 1-去氢皮质醇, 11β,17α,21-三羟基-1,4-孕甾二烯-3,20-二酮
经验公式(希尔记法):
C21H28O5
CAS号:
分子量:
360.44
Beilstein:
1354103
MDL编号:
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

prednisolone

制造商/商品名称

EDQM

mp

240 °C (dec.) (lit.)

应用

pharmaceutical (small molecule)

格式

neat

SMILES字符串

O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@]2([H])[C@@H](O)C[C@@]4(C)[C@@]3([H])CC[C@]4(O)C(CO)=O)=C1

InChI

1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1

InChI key

OIGNJSKKLXVSLS-VWUMJDOOSA-N

基因信息

human ... NR3C1(2908)

正在寻找类似产品? Visit 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Prednisolone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

相关产品

产品编号
说明
价格

象形图

Health hazard

警示用语:

Danger

危险声明

危险分类

Repr. 1B

储存分类代码

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

法规信息

监管及禁止进口产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

为方便起见,与您过往购买产品相关的文件已保存在文档库中。

访问文档库

难以找到您所需的产品或批次号码?

在网站页面上,产品编号会附带包装尺寸/数量一起显示(例如:T1503-25G)。请确保 在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503
货号
-
25G
包装规格/数量

其它示例:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题?欢迎随时联系我们技术服务 寻求帮助

批号可以在产品标签上"批“ (Lot或Batch)字后面找到。

Aldrich 产品

  • 如果您查询到的批号为 TO09019TO 等,请输入去除前两位字母的批号:09019TO。

  • 如果您查询到的批号含有填充代码(例如05427ES-021),请输入去除填充代码-021的批号:05427ES。

  • 如果您查询到的批号含有填充代码(例如 STBB0728K9),请输入去除填充代码K9的批号:STBB0728。

未找到您寻找的产品?

部分情况下,可能未在线提供COA。如果搜索不到COA,可在线索取。

索取COA

Vappu Rantalaiho et al.
Annals of the rheumatic diseases, 73(11), 1954-1961 (2013-08-03)
To study whether adding initial infliximab to remission-targeted initial combination-DMARD treatment improves the long-term outcomes in patients with early rheumatoid arthritis (RA). Ninety-nine patients with early, DMARD-naïve RA were treated with a triple combination of DMARDs, starting with methotrexate (max
Eng Cern Gan et al.
International forum of allergy & rhinology, 4(11), 877-884 (2014-08-20)
The endoscopically magnified operative field in functional endoscopic sinus surgery (FESS) makes even a small amount of bleeding a potentially significant hindrance. It is thought that irrigation with hot saline during surgery may improve surgical field of view by producing
Axel Heidenreich et al.
European journal of cancer (Oxford, England : 1990), 50(6), 1090-1099 (2014-02-04)
Cabazitaxel/prednisone has been shown to prolong survival versus mitoxantrone/prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or after docetaxel. Subsequently, compassionate-use programmes (CUPs) and expanded-access programmes (EAPs) were established worldwide, allowing access to cabazitaxel before
J A P Spijkers-Hagelstein et al.
Leukemia, 28(4), 761-769 (2013-08-21)
Successful treatment results for MLL-rearranged Acute Lymphoblastic Leukemia (ALL) in infants remain difficult to achieve. Significantly contributing to therapy failure is poor response to glucocorticoids (GCs), like prednisone. Thus, overcoming resistance to these drugs may be a crucial step towards
Michael J Stewart et al.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 9(10), 881-890 (2011-06-28)
The incidence of microscopic colitis and its disease burden are increasing, yet there is limited systematic information addressing the use of conventional corticosteroids and budesonide in microscopic colitis. We performed a systematic review and meta-analysis on the short- and long-term

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门